<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30122854</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">0975-1599</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>25</Volume>                    <Issue>2</Issue>                    <PubDate>                        <MedlineDate>2018 Apr-Jun</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Middle East African journal of ophthalmology</Title>                <ISOAbbreviation>Middle East Afr J Ophthalmol</ISOAbbreviation>            </Journal>            <ArticleTitle>Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers.</ArticleTitle>            <Pagination>                <MedlinePgn>91-95</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/meajo.MEAJO_96_18</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this study was to report the results of staging primary uveal melanoma with whole-body (18) fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) and abdominal ultrasound.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">From January 2012, patients with uveal melanoma over 4 mm in thickness were staged with FDG PET/CT and abdominal ultrasound.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Over 2 years, 108 patients with medium-to-large melanoma underwent dual imaging. According to the tumor, node, and metastasis classification, there were 75% T3, 11% T2, and 14% T1 uveal melanomas. Only, three of 108 patients (2.8%) were found to have metastatic uveal melanoma. All three had liver metastases confirmed following biopsy; one of three had additional extrahepatic widespread metastases. In these three patients, liver findings using both imaging techniques were consistent in one patient. In the second case, abdominal ultrasound missed the diagnosis of metastatic disease; however, FDG PET/CT revealed intense metabolic activity of the liver. In the third case, PET/CT missed the liver metastases; however, this was identified on abdominal ultrasound. PET/CT identified incidental second primary malignancies in 10 patients (9%). Second malignancies were found in the lung, breast, colon, thyroid, and adrenal gland. Abdominal ultrasound detected benign hepatic abnormalities in 20 patients (18%).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Whole-body PET/CT and abdominal ultrasound complement each other in the staging of uveal melanoma. Benign hepatic abnormalities found using ultrasound is common. Of importance, a second asymptomatic primary malignancy associated with uveal melanoma was detected almost one in 10 patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cohen</LastName>                    <ForeName>Victoria M L</ForeName>                    <Initials>VML</Initials>                    <AffiliationInfo>                        <Affiliation>Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew's Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pavlidou</LastName>                    <ForeName>Efthymia</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew's Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>DaCosta</LastName>                    <ForeName>Joanna</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew's Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Arora</LastName>                    <ForeName>Amit K</ForeName>                    <Initials>AK</Initials>                    <AffiliationInfo>                        <Affiliation>Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew's Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Szyszko</LastName>                    <ForeName>Teressa</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Barts health NHS Trust, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sagoo</LastName>                    <ForeName>Mandeep S</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew's Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Szlosarek</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Barts health NHS Trust, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>Middle East Afr J Ophthalmol</MedlineTA>            <NlmUniqueID>101521797</NlmUniqueID>            <ISSNLinking>0974-9233</ISSNLinking>        </MedlineJournalInfo>        <SupplMeshList>            <SupplMeshName Type="Disease" UI="C536494">Uveal melanoma</SupplMeshName>        </SupplMeshList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1997 Jul;15(7):2589-95</RefSource>                <PMID Version="1">9215829</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9</RefSource>                <PMID Version="1">14578381</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Surg Oncol. 2006 Sep;32(7):780-4</RefSource>                <PMID Version="1">16765562</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trans Ophthalmol Soc U K. 1980 Apr;100(Pt 1):34-54</RefSource>                <PMID Version="1">7022781</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40</RefSource>                <PMID Version="1">15325198</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2000 Jun;18(12):2406-12</RefSource>                <PMID Version="1">10856100</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2004 Jun 15;22(12):2438-44</RefSource>                <PMID Version="1">15197206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2015 Nov;51(16):2404-12</RefSource>                <PMID Version="1">26278648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 1993 Jan;34(1):1-6</RefSource>                <PMID Version="1">8418248</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S</RefSource>                <PMID Version="1">14736838</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1974 Oct;34(4):1001-4</RefSource>                <PMID Version="1">4424282</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Surg Oncol. 2010 Feb;36(2):189-94</RefSource>                <PMID Version="1">19775851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Ophthalmol. 2004 Aug;88(8):1095-7</RefSource>                <PMID Version="1">15258035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Ophthalmol. 2005 May;123(5):601-4</RefSource>                <PMID Version="1">15883277</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Chromosomes Cancer. 2014 Feb;53(2):177-82</RefSource>                <PMID Version="1">24243779</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Ophthalmol. 2008 Mar;145(3):418-423</RefSource>                <PMID Version="1">18191091</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Melanoma Res. 2010 Dec;20(6):511-6</RefSource>                <PMID Version="1">20890225</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2003 Jul 2;95(13):971-80</RefSource>                <PMID Version="1">12837833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ophthalmology. 1991 Mar;98(3):383-9; discussion 390</RefSource>                <PMID Version="1">2023760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiographics. 2004 Mar-Apr;24(2):523-43</RefSource>                <PMID Version="1">15026598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Ophthalmol. 2005 Oct;89(10):1270-4</RefSource>                <PMID Version="1">16170114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2004 Mar;11(3):290-7</RefSource>                <PMID Version="1">14993024</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Oct 20;23(30):7654-9</RefSource>                <PMID Version="1">16234527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2001 Jul 15;93(2):155-61</RefSource>                <PMID Version="1">11410860</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Oncol. 1998 Dec;21(6):568-72</RefSource>                <PMID Version="1">9856657</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016609" MajorTopicYN="N">Neoplasms, Second Primary</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014604" MajorTopicYN="N">Uveal Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051598" MajorTopicYN="N">Whole Body Imaging</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Abdominal ultrasound</Keyword>            <Keyword MajorTopicYN="N">metastases</Keyword>            <Keyword MajorTopicYN="N">positron-emission tomography/computed tomography scan</Keyword>            <Keyword MajorTopicYN="N">primary Choroidal melanoma</Keyword>            <Keyword MajorTopicYN="N">staging</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30122854</ArticleId>            <ArticleId IdType="doi">10.4103/meajo.MEAJO_96_18</ArticleId>            <ArticleId IdType="pii">MEAJO-25-91</ArticleId>            <ArticleId IdType="pmc">PMC6071338</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>